Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T125565 |
AAL Toxin TD1
|
||
AAL Toxin TD1 是一种有用的有机化合物,可用于生命科学领域的相关研究,其产品编号为 T125565。 | |||
TP1033 |
Transdermal Peptide Disulfide
Transdermal Peptide,TD 1 (peptide) |
||
Transdermal Peptide (TD 1 peptide) is a 11-amino acid peptide, binds toNa+/K+-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide can enhance the transdermal delivery of many macromolecules.Transdermal Pep | |||
T36970 |
STD1T
|
DUB | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Ubiquitination |
STD1T 是一种具有选择性和有效性的脱泛素酶 USP2a 抑制剂,具有潜在的抗癌活性,可降低 HCT116 结肠和 MCF-7 乳腺癌细胞中的细胞周期蛋白 D1 蛋白水平。 | |||
T72553 |
ARTD10/PARP10-IN-1
|
PARP | Chromatin/Epigenetic; DNA Damage/DNA Repair |
ARTD10/PARP10-IN-1 是一种强效性的 PARP 抑制剂,抑制单 ADP 核糖转移酶 ARTD7/PARP15,ARTD8/PARP14,ARTD10/PARP10 和聚 ADP-核糖聚合酶-1 (ARTD1/PARP1),具有潜在的抗癌抗肿瘤活性,可用于研究前列腺癌和乳腺癌。 | |||
T5121 |
TD139
|
Galectin | Immunology/Inflammation |
TD139 是一种吸入型 galectin-3 抑制剂(Kd:14 nM)。 | |||
T79201 |
PTD10
|
PROTACs | PROTAC |
PTD10是一种有效的PROTACBTK降解剂(DC50: 0.5 nM,KD: 2.28nM)。在Ramos和JeKo-1细胞系中,PTD10能够降解BTK,其DC50s分别为0.5和0.6 nM。此外,PTD10通过激活caspase依赖途径和线粒体途径抑制细胞增殖,诱导细胞凋亡(apoptosis),可作为研究B细胞失调模型的工具。 | |||
T75010 | TD1092 | ||
TD1092 是一种泛凋亡抑制蛋白 (IAP) 降解剂,可降解 cIAP1,cIAP2和 XIAP。TD1092 激活细胞凋亡蛋白酶 (apoptosis3/7),并通过促进 IAP 降解,导致癌细胞凋亡 (apoptosis)。同时,TD1092 还能够阻断 TNFα介导的 NF-κB 信号通路,抑制 IKK,IkBα,p65,和 p38 的磷酸化。TD1092 可作为 PROTAC,用于癌症研究。 | |||
T72554 |
ARTD10/PARP10-IN-2
|
||
ARTD10/PARP10-IN-2 是一种强效、非选择性的PARP 抑制剂。ARTD10/PARP10-IN-2 靶向单 ADP 核糖转移酶 (ARTD10/PARP10) 和聚 ADP-核糖聚合酶-1 (ARTD1/PARP1),IC50分别为 2.0 μM,和 9.7 μM。 | |||
T37766 |
Transdermal Peptide (TD 1 (peptide))
|
||
Transdermal Peptide is a 11-amino acid peptide, binds to Na+/K+-ATPase beta-subunit (ATP1B1), and enhances the transdermal delivery of many macromolecules. Transdermal Peptide (TD1) binds to ATP1B1, and mainly interacts with the C-terminus of ATP1B1 in yeast and mammalian cells. The interaction affects the expression and localization of ATP1B1 and epidermal structure, but can be antagonized by the exogenous competitor ATP1B1 or be inhibited by ouabain. Inhibition of Transdermal Peptide binding t... |